Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
RespireRx Pharmaceuticals Inc. (RSPI) generates news primarily through research, clinical development, regulatory and capital markets activities related to its neuromodulator and pharmaceutical cannabinoid programs. Through the RespireRx Group, which includes EndeavourRx LLC and ResolutionRx Ltd, the company reports progress on drug candidates targeting epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from spinal cord injury (SCI), certain neurological orphan diseases and obstructive sleep apnea (OSA).
News updates often highlight preclinical and translational findings for the company’s lead compounds. For example, RespireRx has reported peer-reviewed publications demonstrating that its AMPAkine CX1739 improved bladder function in rodent models of spinal cord injury and that KRM-II-81, its lead GABAkine, suppressed epileptiform activity in human brain tissue slices from a pharmaco-resistant epilepsy patient. Additional releases describe KRM-II-81’s advancement within the NIH HEAL Initiative Preclinical Screening Platform for Pain, where it has shown anti-pain effects in animal models at doses with minimal or no detectable side effects.
Investors and observers can also find announcements about external funding and collaborations, such as a Department of Defense translational research award to Shirley Ryan AbilityLab for a Phase 2A/2B clinical trial of CX1739 in SCI patients and an NIH/NINDS Small Business Innovation Research (SBIR) grant to support IND-enabling work for KRM-II-81 in epilepsy. Company communications further cover strategic steps at ResolutionRx Ltd to advance a new dronabinol formulation for OSA, including use of the Australian R&D Tax Incentive and plans for stock exchange listings.
Regulatory and corporate developments are another key theme in RSPI news. RespireRx has issued releases about SEC correspondence, the Section 12(j) order revoking registration of its securities, and its stated intention to pursue future Form 10 registration. Capital-raising initiatives, including a Regulation D, Rule 506(c) private placement across RespireRx, EndeavourRx and ResolutionRx, are also described. For ongoing context on RSPI, readers can review this news stream for updates on clinical plans, grant awards, licensing agreements, governance changes and the company’s responses to regulatory actions.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced significant advancements in its drug development programs targeting neurological disorders. The company is preparing to publish a review on its GABAkine compound, KRM-II-81, which shows promise in treating epilepsy, chronic pain, anxiety, and depression. Additionally, ongoing collaborations are expected to enhance AMPAkines for spinal cord injury recovery, and innovative formulations of dronabinol are in preclinical development for obstructive sleep apnea. While progress is noted, key compounds have yet to enter human trials, indicating risk in their future success.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) has successfully up-listed from the OTC Pink Market to the OTCQB Venture Market, effective February 8, 2021. The company's ticker symbol has reverted to RSPI from RSPID. RespireRx focuses on developing innovative treatments for conditions such as obstructive sleep apnea and ADHD, leveraging its two main drug platforms: ResolutionRx (pharmaceutical cannabinoids) and EndeavourRx (neuromodulators). The management is considering separating these platforms into subsidiaries to optimize value and attract funding.
RespireRx Pharmaceuticals has been uplisted from the OTC Pink Market to the OTCQB Venture Market as of February 8, 2021. The ticker symbol has changed back to RSPI from RSPID. The company's focus is on developing treatments for various disorders including obstructive sleep apnea, ADHD, and chronic pain through two main drug platforms: ResolutionRx and EndeavourRx. RespireRx aims to enhance asset value by potentially establishing formal subsidiaries and engaging in strategic partnerships and business development efforts. However, there are no guarantees regarding successful transactions.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the publication of a review on CX717, an ampakine that enhances motor nerve function post-spinal cord injury, by Dr. David Fuller. The article in Experimental Neurology highlights CX717's ability to improve phrenic motor nerve activity over 8 weeks, suggesting potential benefits for spinally injured patients. Chief Scientific Officer Arnold Lippa emphasized the intention to advance this research towards human clinical trials, underscoring the company's focus on neuromodulators for treating diverse neurological disorders.